Sangamo Therapeutics, Inc. (SGMO)

NASDAQ: SGMO · Real-Time Price · USD
0.5000
+0.0090 (1.83%)
At close: Jun 16, 2025, 4:00 PM
0.4975
-0.0025 (-0.50%)
After-hours: Jun 16, 2025, 7:57 PM EDT
1.83%
Market Cap 118.80M
Revenue (ttm) 63.76M
Net Income (ttm) -79.45M
Shares Out 237.60M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,607,897
Open 0.4900
Previous Close 0.4910
Day's Range 0.4730 - 0.5036
52-Week Range 0.3040 - 3.1790
Beta 1.21
Analysts Buy
Price Target 4.50 (+800.0%)
Earnings Date Aug 5, 2025

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2000
Employees 183
Stock Exchange NASDAQ
Ticker Symbol SGMO
Full Company Profile

Financial Performance

In 2024, Sangamo Therapeutics's revenue was $57.80 million, a decrease of -67.20% compared to the previous year's $176.23 million. Losses were -$97.94 million, -62.01% less than in 2023.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 800.00% from the latest price.

Price Target
$4.5
(800.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications ...

5 weeks ago - Seeking Alpha

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.

5 weeks ago - Business Wire

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.

5 weeks ago - Business Wire

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS POSTPONES FIRST QUARTER 2025 CONFERENCE CALL TO LATER THE SAME DAY.

5 weeks ago - Business Wire

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.

5 weeks ago - Business Wire

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease.

5 weeks ago - Business Wire

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT).

7 weeks ago - Business Wire

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payme...

2 months ago - Seeking Alpha

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.

2 months ago - Business Wire

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communication...

3 months ago - Seeking Alpha

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results.

3 months ago - Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE.

3 months ago - Business Wire

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE.

4 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo s...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo s...

5 months ago - Accesswire

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo s...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Compan...

5 months ago - Accesswire

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Compan...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (N...

5 months ago - Accesswire

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company...

5 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company...

5 months ago - Accesswire

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc...

5 months ago - Business Wire